Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Plasma cell 3

Conditions

Glioblastoma 4Carcinoma, Non-Small-Cell Lung 4Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Glioma 3Sarcoma 2Nervous System Neoplasms 2Nervous System Diseases 2Melanoma 2Central Nervous System Neoplasms 2Central Nervous System Diseases 2Breast Neoplasms 2Brain Neoplasms 2Brain Diseases 2Astrocytoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Resectable Pancreatic Cancer 1Resectable Esophageal Cancer 1Radiation Pneumonitis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Mesothelial Neoplasm 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Multiple Myeloma × Adjuvants, Immunologic × Clear all
NCT05271630 2026-03-02

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

H. Lee Moffitt Cancer Center and Research Institute

Active not recruiting
69 enrolled
Plasma cell

Multiple Myeloma

NCT02400242 2024-07-09

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

Celgene

Phase 1 Terminated
85 enrolled
Plasma cell

Multiple Myeloma

NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡